"SACUBRIGHT 100: Heart Failure Treatment with Sacubitril and Valsartan"

SACUBRIGHT 100 

Sacubitril (49mg), Valsartan (51mg)

Introduction

Sacubitril (49mg) and Valsartan (51mg) are combined in SACUBRIGHT 100 to form a powerful treatment for chronic heart failure. This combination is a significant advancement in the management of heart failure, offering improved patient outcomes and better quality of life.

Mechanism of Action

Sacubitril is a neprilysin inhibitor that increases levels of beneficial peptides, leading to vasodilation and reduced blood pressure. Valsartan, an angiotensin II receptor blocker (ARB), inhibits the effects of angiotensin II, which helps to relax blood vessels and lower blood pressure. Together, they provide a comprehensive approach to managing heart failure.

Indications

SACUBRIGHT 100 is indicated for:

• Chronic heart failure with reduced ejection fraction (HFrEF)
• Lowering the risk of cardiovascular death and hospitalization due to heart failure
• Alleviating symptoms of heart failure and enhancing patient quality of life

Recommended Dosage

The standard starting dose of SACUBRIGHT 100 is one tablet taken twice daily. Depending on the patient's response and tolerability, the dosage may be adjusted. It is important to follow the healthcare provider's instructions carefully.

Adverse Effects

Some common side effects associated with SACUBRIGHT 100 include:

• Low blood pressure (hypotension)
• Elevated potassium levels (hyperkalemia)
• Impaired kidney function
• Dizziness or lightheadedness
• Persistent cough

Safety Precautions

Patients should discuss their medical history with their healthcare provider before starting SACUBRIGHT 100, especially if they have:

• Renal or hepatic impairment
• A history of angioedema
• Electrolyte disturbances
• Allergic reactions to any component of the medication

Pregnant or nursing women should avoid this medication due to potential risks to the baby.

Benefits of SACUBRIGHT 100

The combination of Sacubitril and Valsartan in SACUBRIGHT 100 offers several benefits, including:

• Enhanced heart function and reduced strain on the heart
• Lower risk of heart failure-related hospitalization
• Improved survival rates for heart failure patients
• Better management of heart failure symptoms, leading to an improved quality of life

Conclusion

SACUBRIGHT 100, combining Sacubitril (49mg) and Valsartan (51mg), represents a significant advancement in heart failure treatment. By addressing multiple pathways involved in heart failure, it offers a comprehensive solution for managing this chronic condition. Patients should consult their healthcare provider to determine if SACUBRIGHT 100 is the right choice for their heart failure management.Steris Healthcare Pvt Ltd, founded by a group of expert professionals in the pharmaceutical industry in February 2018, operates as Sterispharma. This company, which is based in Navi Mumbai, holds certifications from WHO, GMP, and ISO. Its commitment is to provide high-quality drugs at affordable prices to its customers throughout India, following the rigorous guidelines set by the WHO. Steris offers the convenience of an online pharmacy where customers can easily buy medicines and enjoy the benefit of home delivery. At Steris, the mission is to supply a wide array of healthcare products designed to meet the varied needs of the medical community. Whether it is advanced treatments, medications for rare conditions, or basic health necessities, Sterispharma strives to serve the healthcare industry’s broad demands. The extensive product lineup from Steris includes treatments for various health areas such as Cardiology, Asthma, Respiratory issues, Nasal conditions, Diabetes, Endocrinology, Gastroenterology, Orthopedics, Anti-infectives/antibiotics, General Medicine, Urology, Neurology, Nephrology, Oncology, Gynecology, Pediatrics, Dental care, and Dermatology.

  For further information: 

 EMAIL:  info@sterispharma.com  / contact@sterispharma.com   

 CALL/WHATSAPP: 7877551268, 7849827488

   BUY NOW